Zimmer Biomet (NYSE:ZBH) Rating Increased to Buy at Wall Street Zen

robot
Abstract generation in progress

Wall Street Zen upgraded Zimmer Biomet (NYSE:ZBH) from a “hold” to a “buy” rating, despite the stock having a consensus “Hold” rating from other analysts. The medical equipment provider recently reported strong quarterly results, with EPS of $2.09 and revenue of $2.09 billion, exceeding analyst estimates. However, the stock is currently trading below its recent moving averages.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin